Advertisement

Physiologically based toxicokinetic models and their application in human exposure and internal dose assessment

  • David Kim
  • Leena A. Nylander-French
Part of the Experientia Supplementum book series (EXS, volume 99)

Abstract

Human populations may exhibit large interindividual variation in toxicokinetic response to chemical exposures. Rapid developments in dosimetry research have brought medicine and public health closer to understanding the biological basis of this heterogeneity. The toxicokinetic behavior of chemicals is, in part, controlled by the properties of the epithelium surrounding organs, some of which are effective barriers to penetration into the systemic circulation. Physiologically based toxicokinetic (PBTK) models have been developed and used to simulate the mechanism of uptake into the systemic circulation, to extrapolate between doses and exposure routes, and to estimate internal dosimetry and sources of heterogeneity in animals and humans. Recent improvements to PBTK models include descriptions of active transport across biological membranes, carrier-mediated clearance, and fractal kinetics. The expanding area of toxicogenetics has provided valuable insight for delineating toxicokinetic differences between individuals; genetic differences include inherited single nucleotide polymorphisms, copy number variants, and dynamic changes in the methylation pattern of imprinted genes. This chapter discusses the structure of PBTK models and how toxicogenetic information and newer biological descriptions have improved our understanding of variability in response to toxicant exposures.

Keywords

Exposure Assessment Fractal Kinetic Mixed Venous Blood Toxicant Exposure Intestinal Membrane 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Reddy MB, Yang RSH, Clewell HJ III, Andersen ME (2005) Physiologically Based Pharmacokinetic Modeling: Science and Applications. John Wiley & Sons, Hoboken, 420CrossRefGoogle Scholar
  2. 2.
    Rowland M, McLachlan A (1996) Pharmacokinetic considerations of regional administration and drug targeting: influence of site of input in target tissue and flux of binding protein. J Pharmacokinet Biopharm 24: 369–387PubMedCrossRefGoogle Scholar
  3. 3.
    Ramsey JC, Andersen ME (1984) A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans. Toxicol Appl Pharmacol 73: 159–175PubMedCrossRefGoogle Scholar
  4. 4.
    Potts RO, Bommannan DB, Guy RH (1992) Percutaneous absorption. In: H Mukhtar (ed.): Pharmacology of the Skin. CRC Press, Boca Raton, 13–28Google Scholar
  5. 5.
    Johnson LR (2006) Physiology of the Gastrointestinal Tract. Elsevier Academic Press, BurlingtonGoogle Scholar
  6. 6.
    Staats DA, Fisher JW, Connolly RB (1991) Gastrointestinal absorption of xenobiotics in physiologically based pharmacokinetic models. A two-compartment description. Drug Metab Dispos 19: 144–148PubMedGoogle Scholar
  7. 7.
    Withey JR, Collins BT, Collins PG (1983) Effect of vehicle on the pharmacokinetics and uptake of four halogenated hydrocarbons from the gastrointestinal tract of the rat. J Appl Toxicol 3: 249–253PubMedCrossRefGoogle Scholar
  8. 8.
    Vandam LD, Fox JA (1998) Adolf Fick (1829-1901), physiologist: A heritage for anesthesiology and critical care medicine. Anesthesiology 88: 514–518PubMedCrossRefGoogle Scholar
  9. 9.
    Pfitzner J (1976) Poiseuille and his law. Anaesthesia 31: 273–275PubMedCrossRefGoogle Scholar
  10. 10.
    Teorell T (1935) Studies on the “Diffusion Effect” upon ionic distribution. Some theoretical considerations. Proc Natl Acad Sci USA 21: 152–161PubMedCrossRefGoogle Scholar
  11. 11.
    McCarley KD, Bunge AL (2001) Pharmacokinetic models of dermal absorption. J Pharm Sci 90: 1699–1719PubMedCrossRefGoogle Scholar
  12. 12.
    Kim RB (2002) Transporters and xenobiotic disposition. Toxicology 181-182: 291–297PubMedCrossRefGoogle Scholar
  13. 13.
    Raub TJ (2006) P-glycoprotein recognition of substrates and circumvention through rational drug design. Mol Pharmacol 3: 3–25CrossRefGoogle Scholar
  14. 14.
    Sharom FJ (2006) Shedding light on drug transport: Structure and function of the P-glycoprotein multidrug transporter (ABCB1). Biochem Cell Biol 84: 979–992PubMedCrossRefGoogle Scholar
  15. 15.
    Abu-Qare AW, Elmasry E, Abou-Donia MB (2003) A role for P-glycoprotein in environmental toxicology. J Toxicol Environ Health B Crit Rev 6: 279–288PubMedCrossRefGoogle Scholar
  16. 16.
    Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U (2000) Functional polymorphisms of the human multidrugresistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97: 3473–3478PubMedCrossRefGoogle Scholar
  17. 17.
    Marzolini C, Paus E, Buclin T, Kim RB (2004) Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 75: 13–33PubMedCrossRefGoogle Scholar
  18. 18.
    You G, Morris ME (2007) Drug Transporters: Molecular Characterization and Role in Drug Disposition. Wiley-Interscience, HobokenGoogle Scholar
  19. 19.
    Meunier V, Bourrie M, Berger Y, Fabre G (1995) The human intestinal epithelial cell line Caco-2; pharmacological and pharmacokinetic applications. Cell Biol Toxicol 11: 187–194PubMedCrossRefGoogle Scholar
  20. 20.
    Andersen ME, Clewell HJ 3rd, Tan YM, Butenhoff JL, Olsen GW (2006) Pharmacokinetic modeling of saturable, renal resorption of perfluoroalkylacids in monkeys-Probing the determinants of long plasma half-lives. Toxicology 227: 156–164PubMedCrossRefGoogle Scholar
  21. 21.
    Lohitnavy M, Lu Y, Lohitnavy O, Chubb LS, Hirono S, Yang RS (2008) A possible role of multidrug resistance-associated protein 2 (Mrp2) in hepatic excretion of PCB126, and environmental contaminant: PBPK/PD modeling. Toxicol Sci 104: 27–39PubMedCrossRefGoogle Scholar
  22. 22.
    Bassingthwaighte JB, Liebovitch LS, West BJ (1994) Fractal Physiology. Oxford University Press, New YorkGoogle Scholar
  23. 23.
    Obata Y, Sesumi T, Takayama K, Isowa K, Grosh S, Wick S, Sitz R, Nagai T (2000) Evaluation of skin damage caused by percutaneous absorption enhancers using fractal analysis. J Pharm Sci 89: 556–561PubMedCrossRefGoogle Scholar
  24. 24.
    Macheras P (1995) Carrier-mediated transport can obey fractal kinetics. Pharm Res 12: 541–548PubMedCrossRefGoogle Scholar
  25. 25.
    Caroli-Bosc FX, Iliadis A, Salmon L, Macheras P, Montet AM, Bourgeon A, Garraffo R, Delmont JP, Montet JC (2000) Ursodeoxycholic acid modulates cyclosporin A oral absorption in liver transplant recipients. Fundam Clin Pharmacol 14: 601–609PubMedCrossRefGoogle Scholar
  26. 26.
    Higaki K, Yamashita S, Amidon GL (2001) Time-dependent oral absorption models. J Pharmacokinet Pharmacodyn 28: 109–128PubMedCrossRefGoogle Scholar
  27. 27.
    Kopelman R (1986) Rate processes on fractals: Theory, simulations, and experiments. J Stat Phys 41: 185–200CrossRefGoogle Scholar
  28. 28.
    Kopelmam R (1988) Fractal reaction kinetics. Science 241: 1620–1626CrossRefGoogle Scholar
  29. 29.
    Lopez-Quintela MA, Casado J (1989) Revision of the methodology in enzyme kinetics: A fractal approach. J Theor Biol 139: 129–130CrossRefGoogle Scholar
  30. 30.
    Marsh RE, Tuszynski JA (2006) Fractal Michaelis-Menten kinetics under steady state conditions: Application to mibefradil. Pharm Res 23: 2760–2767PubMedCrossRefGoogle Scholar
  31. 31.
    Paschou P, Ziv E, Burchard EG, Choudhry S, Rodriguez-Cintron W, Mahoney MW, Drineas P (2007) PCA-correlated SNPs for structure identification in worldwide human populations. PLoS Genet 3: 1672–1686PubMedCrossRefGoogle Scholar
  32. 32.
    Estivill X, Armengol L (2007) Copy number variants and common disorders: Filling the gaps and exploring complexity in genome-wide association studies. PLoS Genet 3: 1787–1799PubMedCrossRefGoogle Scholar
  33. 33.
    Bird A (2002) DNA methylation patterns and epigenetic memory. Genes Dev 16: 6–21PubMedCrossRefGoogle Scholar
  34. 34.
    Laird P (2003) The power and the promise of DNA methylation markers. Nat Rev Cancer 3: 253–266PubMedCrossRefGoogle Scholar
  35. 35.
    Livingston RJ, von Niederhausern A, Jegga AG, Crawford DC, Carlson CS, Rieder MJ, Gowrisankar S, Aronow BJ, Weiss RB, Nickerson DA (2004) Pattern of sequence variation across 213 environmental response genes. Genome Res 14: 1821–1831PubMedCrossRefGoogle Scholar
  36. 36.
    Kim YD, Lee CH, Nan HM, Kang JW, Kim H (2003) Effects of genetic polymorphisms in metabolic enzymes on the relationships between 8-hydroxydeoxyguanosine levels in human leukocytes and urinary 1-hydroxypyrene and 2-naphthol concentrations. J Occup Health 45: 160–167PubMedCrossRefGoogle Scholar
  37. 37.
    Lee CY, Lee JY, Kang JW, Kim H (2001) Effects of genetic polymorphisms of CYP1A1, CYP2E1, GSTM1, and GSTT1 on the urinary levels of 1-hydroxypyrene and 2-naphthol in aircraft maintenance workers. Toxicol Lett 123: 115–124PubMedCrossRefGoogle Scholar
  38. 38.
    Nan HM, Kim H, Lim HS, Choi JK, Kawamoto T, Kang JW, Lee CH, Kim YD, Kwon EH (2001) Effects of occupation, lifestyle and genetic polymorphisms of CYP1A1, CYP2E1, GSTM1 and GSTT1 on urinary 1-hydroxypyrene and 2-naphthol concentrations. Carcinogenesis 22: 787–793PubMedCrossRefGoogle Scholar
  39. 39.
    Yoshimura K, Hanaoka T, Ohnami S, Ohnami S, Kohno T, Liu Y, Yoshida T, Sakamoto H, Tsugane S (2003) Allele frequencies of single nucleotide polymorphisms (SNPs) in 40 candidate genes for gene-environment studies on cancer: Data from population-based Japanese random samples. J Hum Genet 48: 654–658PubMedCrossRefGoogle Scholar
  40. 40.
    Eberle MA, Rieder MJ, Kruglyak L, Nickerson DA (2006) Allele frequency matching between SNPs reveals an excess of linkage disequilibrium in genic regions of the human genome. PLoS Genet 2: e142CrossRefGoogle Scholar
  41. 41.
    Hinds DA, Stuve LL, Nilsen GB, Halperin E, Eskin E, Ballinger DG, Frazer KA, Cox DR (2005) Whole-genome patterns of common DNA variation in three human populations. Science 307: 1072–1079PubMedCrossRefGoogle Scholar
  42. 42.
    Hinds DA, Kloek AP, Jen M, Chen X, Frazer KA (2006) Common deletions and SNPs are in linkage disequilibrium in the human genome. Nat Genet 38: 82–85PubMedCrossRefGoogle Scholar
  43. 43.
    Elston RC (1995) Linkage and association to genetic markers. Exp Clin Immunogen 12: 129–140Google Scholar
  44. 44.
    Lawrence RW, Evans DM, Cardon LR (2005) Prospects and pitfalls in whole genome association studies. Phil Trans Roy Soc London 360: 1589–1595CrossRefGoogle Scholar
  45. 45.
    Romero R, Kuivaniemi H, Tromp G, Olson J (2002) The design, execution, and interpretation of genetic association studies to decipher complex diseases. Am J Obstet Gynecol 187: 1299–1312PubMedCrossRefGoogle Scholar
  46. 46.
    Zaykin DV, Zhivotovsky LA (2005) Ranks of genuine associations in whole-genome scans. Genetics 171: 813–823PubMedCrossRefGoogle Scholar
  47. 47.
    Kimmel G, Sharan R, Shamir R (2004) Computational problems in noisy SNP and haplotype analysis: Block scores, block identification, and population stratification. INFORMS J Comput 16: 360–370CrossRefGoogle Scholar
  48. 48.
    Devlin B, Roeder K, Bacanu SA (2001) Unbiased methods for population-based association studies. Genet Epidemiol 21: 273–284PubMedCrossRefGoogle Scholar
  49. 49.
    ACGIH (2007) Documentation of the TLVs® and BEIs®. American Conference of Governmental Industrial Hygienist, CincinnatiGoogle Scholar
  50. 50.
    Deutsche Forschungsgemeinschaft, Commission for Investigation of Health Hazards of Chemical Compounds in the Work Area (2007) List of MAK and BAT Values 2006: Maximum Concentrations and Biological Tolerance Values at the Workplace. Wiley-VCH, WeinheimGoogle Scholar

Copyright information

© Birkhäuser Verlag/Switzerland 2009

Authors and Affiliations

  • David Kim
    • 1
  • Leena A. Nylander-French
    • 2
  1. 1.Harvard UniversityBostonUSA
  2. 2.University of North Carolina at Chapel HillChapel HillUSA

Personalised recommendations